Bellevue Group Ag Fibrogen Inc Transaction History

Bellevue Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$18.57 - $35.68 $1.11 Million - $2.14 Million	-60,000 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$31.0 - $55.72 $217,000 - $390,040	7,000 Added 13.21%	60,000 $2.08 Million
Q3 2020 Nov 16, 2020	BUY	$40.47 - $45.5 $2.14 Million - $2.41 Million	53,000 New	53,000 $2.18 Million
Q2 2020 Aug 13, 2020	SELL	$32.57 - $42.83 $1.22 Million - $1.61 Million	-37,600 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$23.3 - $45.96 $20,970 - $41,364	-900 Reduced 2.34%	37,600 $1.31 Million
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $1.33 Million - $1.85 Million	38,500 New	38,500 $1.65 Million
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $1.71 Million - $2.71 Million	-48,800 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $719,544 - $1.01 Million	16,800 Added 52.5%	48,800 $2.65 Million
Q4 2018 Feb 12, 2019	BUY	$37.97 - $60.16 $1.22 Million - $1.93 Million	32,000 New	32,000 $1.48 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $36.6M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.